Abstract：
:The poly(ADP-ribose) polymerase inhibitor rucaparib is approved as monotherapy in the treatment and maintenance settings for women with relapsed ovarian cancer in the European Union and the United States. We review the safety profile of rucaparib in both settings and provide recommendations for the clinical management of the main adverse events (AEs) that may occur during rucaparib treatment. We searched PubMed and congress proceedings for safety data on oral rucaparib monotherapy (600 mg twice daily) from clinical trials involving patients with relapsed ovarian cancer. AE management guidance was developed from clinical trial protocols, rucaparib prescribing information, oncology association guidelines, and author experience. The most frequent any-grade treatment-emergent AEs (TEAEs) included gastrointestinal symptoms, asthenia/fatigue, dysgeusia, anemia/decreased hemoglobin, and increased alanine/aspartate aminotransferase. Across clinical trials, 61.8% of patients had one or more grade 3 or higher TEAEs. Clinicians should employ close follow-up for TEAEs, particularly early in treatment, and educate patients about expected TEAEs and methods for their monitoring and management (e.g., antiemetics for nausea/vomiting, transfusions for hematologic TEAEs, or dose interruptions/reductions for moderate/severe TEAEs). Overall, 16.2% of patients discontinued rucaparib due to TEAEs. Management of AEs that may occur during rucaparib treatment is crucial for patients to obtain optimal clinical benefit by remaining on therapy and to avoid their detrimental impact on quality of life.
journal_name
Target Oncoljournal_title
Targeted oncologyauthors
Lorusso D,García-Donas J,Sehouli J,Joly Fdoi
10.1007/s11523-020-00715-zsubject
Has Abstractpub_date
2020-06-01 00:00:00pages
391-406issue
3eissn
1776-2596issn
1776-260Xpii
10.1007/s11523-020-00715-zjournal_volume
15pub_type
杂志文章abstract：:Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive malignancy with poor outcome occurring in adolescents and young adults. Therapeutic options for patients with advanced disease are limited. Preclinical studies have shown that VEGFR-2 and VEGFA are overexpressed in DSRCT and that DSRCT xenografts wer...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-012-0251-8
更新日期：2013-09-01 00:00:00
abstract：BACKGROUND:Cancer is a multifactorial disease, which makes it difficult to cure. Since more than one defective cellular component is often involved during oncogenesis, combination therapy is gaining prominence in the field of cancer therapeutics. OBJECTIVE:The purpose of this study was to investigate the combinatorial...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-016-0441-x
更新日期：2016-10-01 00:00:00
abstract：BACKGROUND:Immunotherapy based on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment of non-small cell lung cancer (NSCLC). Patients with high PD-L1 expression or DNA mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) cancer are re...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-020-00703-3
更新日期：2020-02-01 00:00:00
abstract：:ABP 980 was developed as a biosimilar to trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), that is indicated for the treatment of HER2-positive metastatic breast cancer, early breast cancer (EBC), and metastatic gastric cancer. ABP 980 is approved in the United States, Europ...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-019-00675-z
更新日期：2019-12-01 00:00:00
abstract：:The influence of tumor infiltrating lymphocytes on tumor growth and response to therapy is becoming increasingly apparent. While much work has focused on the role of T cell responses in anti-tumor immunity, the role of B cells in solid tumors is much less understood. Tumor infiltrating B cells have been found in a var...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-017-0481-x
更新日期：2017-04-01 00:00:00
abstract：BACKGROUND:Serum protein fraction (SPF) is a common parameter reflecting the nutritional and inflammatory status of the human body. However, its role in patients with cancer, particularly those treated with targeted agents, is unknown. OBJECTIVE:We conducted this study to explore the prognostic value of SPF in patient...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-019-00625-9
更新日期：2019-04-01 00:00:00
abstract：:Vemurafenib, a specific inhibitor of mutated BRAF kinase, may activate wild-type BRAF and therefore induce squamous cell skin carcinomas in patients treated for melanoma. All vemurafenib clinical trials excluded patients with multiple primary malignant tumors; therefore, the action of this drug on concurrent BRAF wild...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-015-0384-7
更新日期：2016-04-01 00:00:00
abstract：:With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. This review will focus on these renal tox...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-015-0368-7
更新日期：2015-12-01 00:00:00
abstract：:The currently prevalent somatic mutation theory of carcinogenesis and metastases explicitly assumes that cancer is a cellular disease, i.e. a disease of the control of cell proliferation and/or cell differentiation. Accordingly, explanations should always be sought for at a gene and/or gene product level, regardless o...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-013-0277-6
更新日期：2013-06-01 00:00:00
abstract：:The discovery of chemoresistant cancer stem cells (CSCs) in carcinomas has created the need for therapies that specifically target these subpopulations of cells. Here, we characterized a bispecific targeted toxin that is composed of two antibody fragments and a catalytic protein toxin allowing it to bind two CSC marke...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-013-0290-9
更新日期：2014-09-01 00:00:00
abstract：:δ-Catenin is the only member of the p120 catenin (p120ctn) subfamily whose normal pattern of expression is restricted to the brain. Similar to p120ctn, δ-catenin can bind to the juxtamembrane domain of E-cadherin. We examined the expression of δ-catenin, p120ctn, and E-cadherin using immunohistochemistry in 95 cases o...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-013-0269-6
更新日期：2014-03-01 00:00:00
abstract：BACKGROUND:Sunitinib (S) is a multi-targeted tyrosine kinase inhibitor. It is synergistic with chemotherapy in preclinical models. We hypothesized that sunitinib in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) would be a tolerable and effective regimen in advanced gastric and gastroesophageal jun...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-019-00692-y
更新日期：2020-02-01 00:00:00
abstract：:Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) catalyze the first rate-limiting step in the oxidative metabolism of compounds containing indole rings, including the transformation of the essential amino acid L-tryptophan to N-formyl-L-kynurenine. Through direct and indirect means, IDO exerts bo...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-017-0547-9
更新日期：2018-04-01 00:00:00
abstract：BACKGROUND:Peripheral T-cell lymphoma (PTCL) is associated with poor prognosis, particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue inhibitor, was the first drug approved to treat R/R PTCL. OBJECTIVE:As the distribution of PTCL subtypes differs between populations and few p...
journal_title：Targeted oncology
pub_type： 杂志文章,多中心研究
doi：10.1007/s11523-019-00630-y
更新日期：2019-04-01 00:00:00
abstract：:Despite recent advances that have been made in the therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC), effective management of bone metastases remains a key goal not yet reached. The receptor tyrosine kinase MET and the vascular endothelial growth factor receptor (VEGFR) seem to play an i...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-015-0412-7
更新日期：2016-08-01 00:00:00
abstract：:Elderly and poor performance status advanced non-small cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib and gefitinib, are active agents in the t...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-009-0104-2
更新日期：2009-01-01 00:00:00
abstract：:Atezolizumab (Tecentriq®), a humanized, anti-programmed cell death ligand-1 (PD-L1) monoclonal antibody, in combination with bevacizumab, carboplatin and paclitaxel (ABCP) or with carboplatin and nab-paclitaxel (ACnP) has been approved as first-line treatment for metastatic nonsquamous NSCLC, based on results from the...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-019-00686-w
更新日期：2019-12-01 00:00:00
abstract：:Hypoxia is a critical hallmark of solid tumors and involves enhanced cell survival, angiogenesis, glycolytic metabolism, and metastasis. Hyperbaric oxygen (HBO) treatment has for centuries been used to improve or cure disorders involving hypoxia and ischemia, by enhancing the amount of dissolved oxygen in the plasma a...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-012-0233-x
更新日期：2012-12-01 00:00:00
abstract：:Obinutuzumab (Gazyva®, Gazyvaro®) is a recombinant, monoclonal, humanized and glycoengineered, type II, anti-CD20, IgG1 antibody. It has recently been granted an additional indication for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. In the...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-017-0485-6
更新日期：2017-04-01 00:00:00
abstract：:Sorafenib (Nexavar®) is currently the only systemic agent approved for use in hepatocellular carcinoma (HCC). Its approval was based on the results of the pivotal SHARP and Sorafenib Asia-Pacific (AP) trials in Child-Pugh (CP) class A patients with advanced HCC, which showed significantly longer median overall surviva...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-017-0484-7
更新日期：2017-04-01 00:00:00
abstract：:The ubiquitin (Ub)+proteasome proteolytic pathway is responsible for the selective degradation of the majority of nuclear and cytosolic proteins. The proteasome is a high molecular weight multicatalytic protease that serves as the catalytic core of the complex Ub-dependent protein degradation pathway and is an excitin...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-010-0165-2
更新日期：2010-12-01 00:00:00
abstract：BACKGROUND:In 2017, nivolumab monotherapy was shown to be effective as third- or later-line therapy in patients with advanced gastric or gastroesophageal junction cancer. OBJECTIVE:In this study, we investigated the relationship between the neutrophil-to-lymphocyte ratio (NLR) and the outcomes of nivolumab monotherapy...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-020-00716-y
更新日期：2020-06-01 00:00:00
abstract：:In subsets of gastrointestinal stromal tumors (GISTs), mutations of the KIT and PDGFRA receptor tyrosine kinases correlate with tumor prognosis and response to tyrosine kinase inhibitors (TKIs). Determining genotypes in TKI-resistant GISTs is challenging due to the potential risks and limitations of repeated biopsies ...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-015-0361-1
更新日期：2015-12-01 00:00:00
abstract：BACKGROUND:The WEE1 inhibitor adavosertib (AZD1775) has been investigated in Western patients. OBJECTIVE:This open-label Phase Ib study (NCT02341456) investigated the safety, pharmacokinetics, and clinical activity of adavosertib in combination with carboplatin alone or paclitaxel plus carboplatin in Asian patients wi...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-020-00701-5
更新日期：2020-02-01 00:00:00
abstract：BACKGROUND:The variability in progression-free survival (PFS) and overall survival (OS) among patients with epithelial ovarian cancer (EOC) makes it difficult to reliably predict outcomes. A predictive biomarker of bevacizumab efficacy as first-line therapy in EOC is still lacking. OBJECTIVE:The MITO group conducted a...
journal_title：Targeted oncology
pub_type： 杂志文章,多中心研究
doi：10.1007/s11523-018-0574-1
更新日期：2018-08-01 00:00:00
abstract：:Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotox...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-016-0452-7
更新日期：2017-02-01 00:00:00
abstract：:Mesothelin is a tumor differentiation antigen, which is highly expressed in several solid neoplasms, including pancreatic cancer. Its selective expression on malignant cells and on only a limited number of healthy tissues has made it an interesting candidate for investigation as a diagnostic and prognostic biomarker a...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-018-0567-0
更新日期：2018-06-01 00:00:00
abstract：:Chemotherapy represents the mainstay of non-small cell lung cancer (NSCLC) treatment, but response is usually observed in only one out of three patients. Massive efforts have been carried out to identify biomarkers that might help clinicians to choose appropriate drugs, by identifying potentially sensitive subjects an...
journal_title：Targeted oncology
pub_type： 杂志文章,评审
doi：10.1007/s11523-010-0132-y
更新日期：2010-03-01 00:00:00
abstract：:Data regarding the expression of epidermal growth factor receptor (EGFR) in melanoma and its role in the tumor biology are conflicting. In BRAF V600-mutant melanomas, the expression of EGFR has been associated with acquired resistance to BRAF inhibitors. In this study, we assessed EGFR expression and downstream signal...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-014-0318-9
更新日期：2015-03-01 00:00:00
abstract：:Among neuroendocrine carcinomas of the gut, well-differentiated tumors are highly vascularized, featuring specific characteristics on contrast-enhanced imaging. Well-differentiated neuroendocrine tumors spontaneously harbor hypervascular enhancement, coexisting with areas of necrosis mainly located at the center of tu...
journal_title：Targeted oncology
pub_type： 杂志文章
doi：10.1007/s11523-012-0216-y
更新日期：2012-06-01 00:00:00
